Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021
JAMA · 2024
DOI: 10.1001/jama.2023.26522 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Nitin Vidyasagar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pritzker School of Medicine, The University of Chicago, Chicago, Illinois. Hauptthemen laut MEDLINE: Buprenorphine, Narcotic Antagonists, Opioid-Related Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This study assesses the proportion of US substance use and mental health care facilities that offered any medications for opioid use disorder and, specifically, long-acting injectable buprenorphine in 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pritzker School of Medicine, The University of Chicago, Chicago, Illinois.
- Department of Psychiatry & Behavioral Neuroscience, The University of Chicago, Chicago, Illinois.
- Department of Medicine, The University of Chicago, Chicago, Illinois.
Zitieren
APA
Vidyasagar, N., Bunting, S. R., Arora, V. M., & Ari, M. (2024). Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021. JAMA. https://doi.org/10.1001/jama.2023.26522
Vancouver
Vidyasagar N, Bunting SR, Arora VM, Ari M. Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021. JAMA. 2024. doi:10.1001/jama.2023.26522
BibTeX
@article{Vidyasagar2024,
author = {Vidyasagar, Nitin and Bunting, Samuel R and Arora, Vineet M and Ari, Mim},
title = {Availability of Long-Acting Injectable Buprenorphine at Substance Use Treatment Facilities in 2021},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2023.26522}
}
EUVIMED